Evidence map›Paper›PMID 41449236›Full record

ArticleAnnals of surgical oncology2026

Feasibility of Omitting Axillary Dissection after Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence: A Single-Center Retrospective Study.

Uta Nakadaira, Takehiko Sakai, Akiko Ogiya, Yuka Inoue, Tetsuyo Maeda, Natsue Uehiro, Nami Yamashita, Akemi Kataoka, Takayuki Ueno

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Uta NakadairaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Takehiko SakaiDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. takehiko.sakai@jfcr.or.jp.
Akiko OgiyaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yuka InoueDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuyo MaedaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Natsue UehiroDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nami YamashitaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Akemi KataokaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Takayuki UenoDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRepeat sentinel lymph node biopsy (re-SLNB) is increasingly performed in patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS). However, evidence on its feasibility and postsurgical lymphatic alterations remains limited. We evaluated the clinical feasibility and drainage patterns of re-SLNB in patients with IBTR who were initially diagnosed with sentinel node-negative (pN0sn) disease but did not undergo axillary lymph node dissection (ALND). PATIENTS AND

methodsWe retrospectively reviewed patients who developed IBTR after BCS and sentinel lymph node biopsy (SLNB; pN0sn) at our institution, between January 2000 and December 2019. All patients underwent re-SLNB guided by preoperative radioisotope lymphoscintigraphy; ALND was omitted if re-SLNB was negative. Clinicopathological data were obtained from institutional databases and medical records.

resultsAmong the 97 eligible patients, 75 (group 1) had sentinel lymph nodes (SLN) identified, retrieved, and confirmed as negative in the ipsilateral axilla, and 22 (group 2) had no SLN identified in the ipsilateral axilla, including those with drainage to alternative basins. In group 1, successful mapping and negative re-SLNB were associated with low axillary recurrence (1.8%) and distant recurrence (4.5%) during a median follow-up of 73 months.

conclusionsRe-SLNB using preoperative radioisotope lymphoscintigraphy is technically feasible in most patients with IBTR and a prior pN0sn status. These findings support re-SLNB as a reliable and less invasive alternative to ALND in appropriately selected patients, suggesting the importance of preoperative lymphatic mapping for surgical planning.

Indexed as

Breast NeoplasmsLymph Node ExcisionNeoplasm Recurrence, LocalSentinel Lymph Node BiopsyAdultAgedAxillaFeasibility StudiesFemaleFollow-Up StudiesHumansLymphoscintigraphyMastectomy, SegmentalMiddle AgedPrognosisRetrospective StudiesAxillary lymph node dissectionBreast cancerIpsilateral breast tumor recurrenceLymphatic drainage mappingSentinel lymph node biopsy

Identifiers

PMID41449236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.